Aqueous humor monocyte chemoattractant protein-1 predicted long-term visual outcome of proliferative diabetic retinopathy undergone intravitreal injection of bevacizumab and vitrectomy

PURPOSE: We aim to investigate the risk factors associated with the prognosis of proliferative diabetic retinopathy (PDR) after a sequential treatment of intravitreal injection of bevacizumab (IVB) and pars plana vitrectomy (PPV).

METHODS: In this cohort study, 63 eyes from 55 patients (21 females) diagnosed with PDR, who needed PPV for non-clearing vitreous hemorrhage or fibrovascular membrane proliferation were enrolled. All the eyes underwent IVB followed by PPV. Anterior chamber tap was performed at the beginning of both procedures to evaluate the concentration of vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-8, and monocyte chemoattractant protein (MCP)-1.

RESULTS: Forty-seven patients (54 eyes) were followed over six months, averaging 12±5 (6-19) months. The concentration of VEGF significantly decreased after IVB (P<0.001), while other cytokines did not change significantly. The aqueous humor level of IL-8 after IVB (R = 0.378, P = 0.033), MCP-1 before (R = 0.368, P = 0.021) and after (R = 0.368, P = 0.038) IVB, and combined phacoemulsification (R = 0.293, P = 0.032) was correlated with the logMAR visual acuity at the last follow-up. Multivariate analysis showed that MCP-1 was the predictor for a worse visual outcome (B = 0.108, 95% CI 0.013-0.202; P = 0.027).

CONCLUSIONS: MCP-1 was a predictor for the unfavorable visual outcome of PDR after IVB pretreatment and PPV.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:16

Enthalten in:

PloS one - 16(2021), 3 vom: 21., Seite e0248235

Sprache:

Englisch

Beteiligte Personen:

Lei, Jianqin [VerfasserIn]
Ding, Guolong [VerfasserIn]
Xie, Anming [VerfasserIn]
Hu, Yaguang [VerfasserIn]
Gao, Ning [VerfasserIn]
Fan, Xiaojuan [VerfasserIn]

Links:

Volltext

Themen:

2S9ZZM9Q9V
Bevacizumab
CCL2 protein, human
Chemokine CCL2
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Anmerkungen:

Date Completed 11.10.2021

Date Revised 11.10.2021

published: Electronic-eCollection

Citation Status MEDLINE

doi:

10.1371/journal.pone.0248235

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM322245761